 BD Becton, Dickinson and Company NYSE: BDX, a leading global medical technology company, today announced that the U.S. Food and Drug Administration FDA granted Emergency Use Authorization EUA for a rapid, point-of-care, SARS-CoV-2 diagnostic test for use with its broadly available BD VeritorTM Plus System. The launch of this new assay that delivers results in 15 minutes on an easy-to-use, highly portable instrument is critical for improving access to COVID-19 diagnostics because it enables real-time results and decision making while the patient is still onsite. 